Akari Therapeutics, Plc
AKTX
$10.73
$1.2112.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.17M | 2.14M | 1.98M | 2.45M | 2.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.63M | 3.23M | 2.22M | 3.12M | 3.53M |
| Operating Income | -3.63M | -3.23M | -2.22M | -3.12M | -3.53M |
| Income Before Tax | -15.31M | -5.21M | -7.49M | -1.90M | -3.71M |
| Income Tax Expenses | -859.00K | 85.00K | -1.09M | -- | -- |
| Earnings from Continuing Operations | -14.46M | -5.30M | -6.40M | -1.90M | -3.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.46M | -5.30M | -6.40M | -1.90M | -3.71M |
| EBIT | -3.63M | -3.23M | -2.22M | -3.12M | -3.53M |
| EBITDA | -- | -3.22M | -2.22M | -3.12M | -3.52M |
| EPS Basic | -779.00K | -392.42K | -627.01K | -192.68K | -434.38K |
| Normalized Basic EPS | -1.41 | -0.58 | -1.62 | -2.45 | -3.44 |
| EPS Diluted | -779.00K | -392.42K | -627.01K | -192.68K | -434.38K |
| Normalized Diluted EPS | -1.41 | -0.58 | -1.62 | -2.45 | -3.44 |
| Average Basic Shares Outstanding | 1.48M | 1.08M | 816.60K | 786.80K | 682.40K |
| Average Diluted Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |